Screener
Veradermics MANE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Issuance of Series B preferred stock, net of issuance costs paid | — | 8,423 |
| Initial public offering, net of issuance costs paid | 269,102 | — |
| Exercise of stock options | 11 | — |
| Net cash provided by financing activities | 269,113 | 8,423 |
| Net increase (decrease) in cash and cash equivalents | 146,646 | (20,644) |
| Cash and cash equivalents—beginning of period | 21,766 | 53,084 |
| Cash and cash equivalents—end of period | $168,412 | $32,440 |
| Supplemental schedule of noncash activities: |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's financing cash flow?
- Veradermics (MANE) reported financing cash flow of $269.11M in Q1 2026.
- How has Veradermics's financing cash flow changed year-over-year?
- Veradermics's financing cash flow increased by 3095.0% year-over-year, from $8.42M to $269.11M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Veradermics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude